You say that to justify the current market cap the NPAT should be $100M at a minimum. That would be a PE ratio of 15.9.
I'm not sure that you are being serious.
Do you realise that such a P/E would be seriously out of wack for a growth stock?
For comparison, here are the P/Es of two very large Aussie health tech stocks: Cochlear's is 75 and Resmed's is 52. Neither has the same potential growth rate as PNV.
I suggest that with an NPAT of $100M the likely P/E of Polynovo would be anywhere from 75 to 275 given that it's potential for high growth would still be great. And that would give an sp range of $12 to $40.
I don't expect an NPAT of $100M to come next year or the next but it won't be long after.
Ann: FY21 BTM Revenue Results, page-128
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.39 |
Change
0.000(0.00%) |
Mkt cap ! $1.650B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.41 | $2.37 | $1.760M | 736.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 23241 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.39 | 381 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |